ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-β pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis

Fagan, Anne M.; Christopher, Erin; Taylor, Jennie W.; Parsadanian, Maia; Spinner, Michael; Watson, Melanie; Fryer, John D.; Wahrle, Suzanne; Bales, Kelly R.; Paul, Steven M.; Holtzman, David M.

doi:10.1016/s0002-9440(10)63399-8

Cited by 54Alzheimer's disease research and treatmentsCholesterol and Lipid MetabolismDementia and Cognitive Impairment Research

ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-β pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis

Open access

Fagan, Anne M., Christopher, Erin, Taylor, Jennie W., Parsadanian, Maia, Spinner, Michael, Watson, Melanie, Fryer, John D., Wahrle, Suzanne +3 more·2004·The American Journal of Pathology

DOI 10.1016/s0002-9440(10)63399-8PMC PMC1618648

Open this paper in CoChat — free account Open PDF

Abstract

Epidemiological studies suggest links between cholesterol metabolism and Alzheimer's disease (AD), with hypercholesterolemia associated with increased AD risk, and use of cholesterol-lowering drugs associated with decreased risk. Animal models using cholesterol-modifying dietary or pharmacological interventions demonstrate similar findings. Proposed mechanisms include effects of cholesterol on the metabolism of amyloid-beta (Abeta), the protein that deposits in AD brain. To investigate the effect of genetic alterations in plasma cholesterol on Abeta pathology, we crossed the PDAPP transgenic mouse model of AD-like cerebral amyloidosis to apolipoprotein AI-null mice that have markedly reduced plasma cholesterol levels due to a virtual absence of high density lipoproteins, the primary lipoprotein in mice. Interestingly and in contrast to models using non-physiological high fat diets or cholesterol-lowering drugs to modify plasma cholesterol, we observed no differences in Abeta pathology in PDAPP mice of the various apoAI genotypes despite robust differences in plasma cholesterol levels between the groups. Absence of apoAI also resulted in reductions in brain but not cerebrospinal fluid cholesterol, but had no effect on brain apolipoprotein E levels. These and other data suggest that it is perhaps the level of brain apolipoprotein E, not cholesterol per se, that plays a primary role in brain Abeta metabolism.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0002-9440(10)63399-8

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

ApoA-I deficiency did not alter amyloid pathology in vivo.
“ApoA-I deficiency did not alter amyloid pathology (Fagan et al., 2004), while apoJ deficiency significantly reduced fibrillar amyloid plaque formation and neuritic toxicity in a mouse model of amyloidosis (DeMattos et al., 2002).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Fagan et al., 2004
Crossing apoA-I-deficient mice with APP transgenic mice did not alter Aβ deposition in the brain.
“By contrast, crossing apoA-I-deficient mice with APP transgenic mice did not alter Aβ deposition in the brain (Fagan et al., 2004)”
From Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide (2012) · cites this paper as Fagan et al., 2004

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059 · see citing works
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · see citing works
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · see citing works
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981 · see citing works
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,748 · see citing works
Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525 · see citing works
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G., & Siegel, G. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,499 · see citing works
Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons
Simons, M., Keller, P., Strooper, B. D., Beyreuther, K. T., Dotti, C. G., & Simons, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6460 · Cited by 1,162 · see citing works
Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo
Fassbender, K. C., Simons, M., Bergmann, C., Stroick, M., Lütjohann, D., Keller, P., Runz, H., Kühl, S., Bertsch, T., von Bergmann, K., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081620098 · Cited by 1,078 · see citing works
Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model
Refolo, L. M., Pappolla, M. A., Malester, B., LaFrancois, J. J., Bryant‐Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., & Duff, K. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0304 · Cited by 994 · see citing works
New stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940 · see citing works
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease
Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · see citing works
Self-citation
Dietary fat intake and the risk of incident dementia in the Rotterdam study
Kalmijn, S., Launer, L. J., Ott, A., Witteman, J. C. M., Hofman, A., & Breteler, M. M. B. (1997) · Annals of Neurology · doi:10.1002/ana.410420514 · Cited by 895 · see citing works
Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments
Ma, J., Yee, A., Brewer, H. B., Das, S., & Potter, H. (1994) · Nature · doi:10.1038/372092a0 · Cited by 871 · see citing works
Alzheimer's disease: the cholesterol connection
Puglielli, L., Tanzi, R. E., & Kovacs, D. M. (2003) · Nature Neuroscience · doi:10.1038/nn0403-345 · Cited by 864 · see citing works
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830 · see citing works
Self-citation
Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain.
Pitas, R. E., Boyles, J. K., Lee, S. H., Hui, D., & Weisgraber, K. H. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47945-8 · Cited by 714 · see citing works
Statins do more than just lower cholesterol
Vaughan, C. J., Murphy, M. B., & Buckley, B. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)05190-2 · Cited by 699 · see citing works
Serum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease
Notkola, I.-L., Sulkava, R. O., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J., & Nissinen, A. (1998) · Neuroepidemiology · doi:10.1159/000026149 · Cited by 666 · see citing works
Amyloid precursor protein processing and Aβ 42 deposition in a transgenic mouse model of Alzheimer disease
Johnson‐Wood, K., Lee, M., Motter, R. N., Hu, K., Gordon, G., Barbour, R., Khan, K., Gordon, M. N., Tan, H. T., Games, D., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.4.1550 · Cited by 634 · see citing works
A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease
Refolo, L. M., Pappolla, M. A., LaFrancois, J. J., Malester, B., Schmidt, S. D., Thomas-Bryant, T., Tint, G. S., Wang, R., Mercken, M. H., Petanceska, S. S., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0422 · Cited by 521 · see citing works
Apolipoprotein E is essential for amyloid deposition in the APP V717F transgenic mouse model of Alzheimer's disease
Bales, K. R., Verina, T., Cummins, D. J., Du, Y., Dodel, R. C., Saura, J., Fishman, C. E., DeLong, C. A., Piccardo, P., Petegnief, V., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15233 · Cited by 486 · see citing works
Self-citation
Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26‐week randomized, placebo‐controlled, double‐blind trial
Simons, M., Schwärzler, F., Lütjohann, D., von Bergmann, K., Beyreuther, K. T., DICHGANS, J., Wormstall, H., Hartmann, T., & Schulz, J. B. (2002) · Annals of Neurology · doi:10.1002/ana.10292 · Cited by 415 · see citing works
Cholesterol-dependent Formation of GM1 Ganglioside-bound Amyloid β-Protein, an Endogenous Seed for Alzheimer Amyloid
Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y., & Matsuzaki, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100252200 · Cited by 406 · see citing works
Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease
Jarvik, G. P., Wijsman, E. M., Kukull, W. A., Schellenberg, G. D., Yu, C., & Larson, E. B. (1995) · Neurology · doi:10.1212/wnl.45.6.1092 · Cited by 371 · see citing works
Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.
Linton, M. F., Gish, R., Hubl, S. T., Bütler, E., Esquivel, C., Bry, W. I., Boyles, J. K., Wardell, M. R., & Young, S. G. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115288 · Cited by 367 · see citing works
Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease
DeMattos, R. B., O'dell, M. A., Parsadanian, M., Taylor, J. W., Harmony, J. A. K., Bales, K. R., Paul, S. M., Aronow, B. J., & Holtzman, D. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162228299 · Cited by 359 · see citing works
Self-citation
Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease
Holtzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., & Paul, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6179 · Cited by 349 · see citing works
Self-citation
The role of cholesterol in the biosynthesis of β-amyloid.
Frears, E. R., Stephens, D. J., Walters, C. E., Davies, H., & Austen, B. (1999) · Neuroreport · doi:10.1097/00001756-199906030-00014 · Cited by 323 · see citing works
Elevated Low-Density Lipoprotein in Alzheimer's Disease Correlates with Brain Aβ 1–42 Levels
Kuo, Y., Emmerling, M. R., Bisgaier, C. L., Essenburg, A. D., Lampert, H. C., Drumm, D. A., & Roher, A. E. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9652 · Cited by 312 · see citing works
Familial Deficiency of Apolipoproteins A-I and C-III and Precocious Coronary-Artery Disease
Norum, R. A., Lakier, J. B., Goldstein, S., Angel, A., Goldberg, R. B., Block, W. D., Noffze, D. K., Dolphin, P. J., Edelglass, J. W., Bogorad, D. D., et al. (1982) · New England Journal of Medicine · doi:10.1056/nejm198206243062503 · Cited by 303 · see citing works
Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease
Fagan, A. M., Watson, M., Parsadanian, M., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0483 · Cited by 290 · see citing works
Self-citation
Apolipoproteins in human cerebrospinal fluid.
Roheim, P. S., Carey, M., Forte, T., & Vega, G. L. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4646 · Cited by 282 · see citing works
Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease☆
Merched, A. J., Xia, Y., Visvikis‐Siest, S., Sérot, J., & Siest, G. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00103-7 · Cited by 273 · see citing works
Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E
Castano, E. M., Prelli, F., Wisniewski, T., Golabek, A., Kumar, R. A., Soto, C., & Frangione, B. (1995) · Biochemical Journal · doi:10.1042/bj3060599 · Cited by 267 · see citing works
Modulation of Secreted β-Amyloid Precursor Protein and Amyloid β-Peptide in Brain by Cholesterol
Howland, D., Trusko, S. P., Savage, M. J., Reaume, A. G., Lang, D. M., Hirsch, J. D., Maeda, N., Siman, R., Greenberg, B., Scott, R. W., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.16576 · Cited by 254 · see citing works
Plaque‐associated disruption of CSF and plasma amyloid‐β (Aβ) equilibrium in a mouse model of Alzheimer's disease
Demattos, R. B., Bales, K. R., Parsadanian, M., O'Dell, M. A., Foss, E. M., Paul, S. M., & Holtzman, D. M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00889.x · Cited by 253 · see citing works
Self-citation
Pathophysiology of reverse cholesterol transport. Insights from inherited disorders of lipoprotein metabolism.
Reichl, D., & Miller, N. E. (1989) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.9.6.785 · Cited by 238 · see citing works
Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease.
Schaefer, E. J., Heaton, W. H., Wetzel, M. G., & Brewer, H. B. (1982) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.2.1.16 · Cited by 233 · see citing works
Unique Lipoproteins Secreted by Primary Astrocytes From Wild Type, apoE (−/−), and Human apoE Transgenic Mice
Fagan, A. M., Holtzman, D. M., Munson, G., Mathur, T., Schneider, D., Chang, L. K., Getz, G. S., Reardon, C. A., Lukens, J., Shah, J. A., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.30001 · Cited by 222 · see citing works
Self-citation
Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins.
Sun, Y., Wu, S., Bu, G., Onifade, M. K., Patel, S. N., LaDu, M. J., Fagan, A. M., & Holtzman, D. M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03261.1998 · Cited by 213 · see citing works
Self-citation
Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I.
Williamson, R., Lee, D., Hagaman, J. R., & Maeda, N. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.7134 · Cited by 207 · see citing works
Apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred
Pastor, P., Roe, C. M., Villegas, A., Bedoya, G., Chakraverty, S., García, G., Tirado, V., Norton, J., Ríos, S., Martínez, M., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10636 · Cited by 194 · see citing works
Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice.
Li, H., Reddick, R. L., & Maeda, N. (1993) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.13.12.1814 · Cited by 189 · see citing works
Brain Expression of Apolipoproteins E, J, and A‐I in Alzheimer's Disease
Harr, S. D., Uint, L., Hollister, R. D., Hyman, B. T., & Mendez, A. J. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062429.x · Cited by 182 · see citing works
Lipid Binding to Amyloid β‐Peptide Aggregates: Preferential Binding of Cholesterol as Compared with Phosphatidylcholine and Fatty Acids
Avdulov, N. A., Chochina, S. V., Igbavboa, U., Warden, C. S., Vassiliev, A. V., & Wood, W. G. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69041746.x · Cited by 180 · see citing works
Alterations of Alzheimer's Disease in the Cholesterol‐fed Rabbit, Including Vascular Inflammation: Preliminary Observations
Sparks, D. L., Kuo, Y., Roher, A. E., MARTIN, T., & Lukas, R. J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06384.x · Cited by 178 · see citing works
Cholesterol Accumulates in Senile plaques of Alzheimer Disease patients and in Transgenic APPswMice
Mori, T., Paris, D., Town, T., Rojiani, A. M., Sparks, D. L., DelleDonne, A., Crawford, F., Abdullah, L. I., Humphrey, J., Dickson, D. W., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.778 · Cited by 175 · see citing works
APOE genotype, plasma lipids, lipoproteins, and AD in community elderly
Romas, S. N., Tang, M.-X., Berglund, L., & Mayeux, R. P. (1999) · Neurology · doi:10.1212/wnl.53.3.517 · Cited by 168 · see citing works
The Soluble Form of Alzheimer′s Amyloid β Protein Is Complexed to High Density Lipoprotein 3 and Very High Density Lipoprotein in Normal Human Plasma
Koudinov, A. R., Matsubara, E., Frangione, B., & Ghiso, J. A. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2788 · Cited by 141 · see citing works
Biochemical Characterization of Alzheimer's Soluble Amyloid Beta Protein in Human Cerebrospinal Fluid: Association with High Density Lipoproteins
Koudinov, A. R., Koudinova, N. V., Kumar, A. R., Beavis, R. C., & Ghiso, J. A. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0940 · Cited by 129 · see citing works
Novel Role for Apolipoprotein E in the Central Nervous System
Han, X., Cheng, H., Fryer, J. D., Fagan, A. M., & Holtzman, D. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212340200 · Cited by 126 · see citing works
Self-citation
Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide
Fassbender, K. C., Stroick, M., Bertsch, T., Ragoschke, A., Kuehl, S., Walter, S., Walter, J., Brechtel-Curth, K., Muehlhauser, F., von Bergmann, K., et al. (2002) · Neurology · doi:10.1212/wnl.59.8.1257 · Cited by 119 · see citing works
Increased amyloid- levels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet.
Levin-Allerhand, J. A., Lominska, C. E., & Smith, J. D. (2002) · PubMed · Cited by 118 · see citing works
Treatment with Simvastatin in Patients with Alzheimer’s Disease Lowers Both α- and β-Cleaved Amyloid Precursor Protein
Sjögren, M. J. C., Gustafsson, K., Syversen, S., Olsson, A., Edman, Å., Davidsson, P., Wallin, A., & Blennow, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000069989 · Cited by 107 · see citing works
Geometria degli indivisibili
Cavalieri, B., & Lombardo-Radice, L. (1966) · Unione tipografico-editrice torinese eBooks · Cited by 103 · see citing works
Cholesterol, Aβ and Alzheimer's disease
Hartmann, T. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01990-1 · Cited by 98 · see citing works
ApoA-I knockout mice: characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes
Plump, A. S., Azrolan, N., Odaka, H., Wu, L., Jiang, X. L., Tall, A. R., Eisenberg, S., & Breslow, J. L. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37227-8 · Cited by 93 · see citing works
MK-801 neurotoxicity in male mice: histologic effects and chronic impairment in spatial learning
Wozniak, D. F., Brosnan-Watters, G., Nardi, A. M. D., McEwen, M. L., Corso, T. D., Olney, J. W., & Fix, A. S. (1996) · Brain Research · doi:10.1016/0006-8993(95)01230-3 · Cited by 87 · see citing works
Synthesis of apolipoprotein AI by peripheral tissues of the rooster. A possible mechanism of cellular cholesterol efflux.
Blue, M. L., Ostapchuk, P., Gordon, J. S., & Williams, D. L. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33945-0 · Cited by 86 · see citing works
Pharmacological concentrations of the HMG-COA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta -amyloid peptide em in vitro em and in patients
Buxbaum, J. D. (2002) · Frontiers in bioscience · doi:10.2741/a739 · Cited by 82 · see citing works
A DNA insertion in the apolipoprotein A-I gene of patients with premature atherosclerosis
Karathanasis, S. K., Zannis, V. I., & Breslow, J. L. (1983) · Nature · doi:10.1038/305823a0 · Cited by 79 · see citing works
Expression of Apolipoprotein A‐I in Porcine Brain Endothelium In Vitro
Möckel, B., Zinke, H., Flach, R., Weiß, B., Weiler-Guettler, H., & Gassen, H. G. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62020788.x · Cited by 76 · see citing works
APOE ε4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome
Deb, S., Braganza, J., Norton, N., Williams, H., Kehoe, P. G., Williams, J., & Owen, M. J. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.5.468 · Cited by 71 · see citing works
Human apolipoprotein E4 accelerates β‐amyloid deposition in APPsw transgenic mouse brain
Carter, D. B., Dunn, E., McKinley, D. D., Stratman, N. C., Boyle, T. P., Kuiper, S. L., Oostveen, J. A., Weaver, R. J., Boller, J. A., & Gurney, M. E. (2001) · Annals of Neurology · doi:10.1002/ana.1134 · Cited by 67 · see citing works
Differential effects of lovastatin treatment on brain cholesterol levels in normal and ApoE-deficient mice
Eckert, G. P., Kirsch, C., & Mueller, W. E. (2001) · Neuroreport · doi:10.1097/00001756-200104170-00003 · Cited by 67 · see citing works
Synthesis of Apolipoprotein A‐1 in Pig Brain Microvascular Endothelial Cells
Weiler-Guettler, H., Sommerfeldt, M., Papandrikopoulou, A., Mischeck, U., Bonitz, D., Frey, A., Grupe, M., Scheerer, J., & Gassen, H. G. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01892.x · Cited by 55 · see citing works
Increased density of cortical apolipoprotein E immunoreactive neurons in rabbit brain after dietary administration of cholesterol
Sparks, D. L., Liu, H., Gross, D. R., & Scheff, S. W. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11357-6 · Cited by 49 · see citing works
Cholesterol, Aβ and Alzheimer's disease
Hartmann, T. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(01)00008-x · Cited by 49 · see citing works
Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins
Naidu, A., Xu, Q., Catalano, R., & Cordell, B. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03480-7 · Cited by 46 · see citing works
Brain region-dependent increases in ?-amyloid and apolipoprotein E levels in hypercholesterolemic rabbits
Wu, C.-W., Liao, P., Lin, C., Kuo, C.-J., Chen, S.-T., Chen, H., & Kuo, Y. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0809-1 · Cited by 40 · see citing works
Secretion of apolipoprotein E by an astrocytoma cell line
Krul, E. S., & Tang, J. (1992) · Journal of Neuroscience Research · doi:10.1002/jnr.490320212 · Cited by 39 · see citing works
Biosynthesis of high density lipoprotein by chicken liver: intracellular transport and proteolytic processing of nascent apolipoprotein A-1.
Banerjee, D., Mukherjee, T. K., & Redman, C. M. (1985) · The Journal of Cell Biology · doi:10.1083/jcb.101.4.1219 · Cited by 30 · see citing works
Effects of Genotype and Diet on Cholesterol Efflux into Plasma and Lipoproteins of Normal, Apolipoprotein A-I-, and Apolipoprotein E-Deficient Mice
Huang, Y., Zhu, Y., Langer, C., Raabe, M., Wu, S., Wiesenhütter, B., Seedorf, U., Maeda, N., Assmann, G., & von Eckardstein, A. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.10.2010 · Cited by 24 · see citing works
Child abuse and the clinical course of drug misuse
Browne, R., & O’Connor, J. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.177.5.469 · Cited by 8 · see citing works
Apolipoprotein E, Alzheimer's disease and Down's syndrome
Prasher, V. P., & Haque, S. M. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.177.5.469-a · Cited by 7 · see citing works
Diagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2 · see citing works
Self-citation
Modulation of Alzheimers Amyloidosis by Statins: Mechanisms of Action
Petanceska, S. S., Pappolla, M. A., & Refolo, L. M. (2003) · Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents · doi:10.2174/1568013033358644 · Cited by 1 · see citing works
Untitled work
(1999) · doi:10.1002/1531-8249(199904)45:4
Untitled work
Khan (2000) · doi:10.1002/1531-8249(200008)48:2
Self-citation

Flagged first, then by citations

Research works printed but not linked: 6

Mori T, Paris D, Town T, Rojiani A, Sparks D, Delledonne A, Crawford F, Abdullah L, Humphrey J, Dickson D, Mullan M: Cholesterol accu- mulates in senile plaques of Alzheimer disease patients and in trans- genic APP sw mice. J Neuropathol Exp Neurol 2001, 60:778 -785
Fagan A, Younkin L, Morris J, Fryer J, Cole T, Younkin S, Holtzman D: Differences in the A␤40/A␤42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol 2000, 48:201-210
Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Hsiao-Ashe K, Irizarry MC, Hyman BT: ApoE is required for neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer's disease. Ann Neurol 2000, 47:739 -747
Sun Y, Wu S, Bu G, Onifade MK, Patel SN, LaDu MJ, Fagan AM, Holtzman DM: GFAP-apoE transgenic mice: astrocyte-specific ex- pression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci 1998, 18:3261-3272
Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH: Lipoproteins and their receptors in the central nervous system. J Biol Chem 1987, 262:14352-14360
Petanceska S, Papolla M, Refolo L: Modulation of Alzheimer's amy- loidosis by statins: mechanisms of action. Curr Med Chem Immunol Endosc Metab Agents 2003, 3:233-243

Sorted by citations

The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · see citing works
Self-citation
Sorting through the Cell Biology of Alzheimer's Disease: Intracellular Pathways to Pathogenesis
Small, S. A., & Gandy, S. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.001 · Cited by 320 · see citing works
Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide
Hashimoto, T., Serrano-Pozo, A., Hori, Y., Adams, K. W., Takeda, S., Banerji, A. O., Mitani, A., Joyner, D., Thyssen, D. H., Bacskai, B. J., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1542-12.2012 · Cited by 294 · see citing works
Self-citation
Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice
Koldamova, R., Staufenbiel, M., & Lefterov, I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504513200 · Cited by 350 · see citing works
Cholesterol homeostasis in neurons and glial cells
Vance, J. E., Hayashi, H., & Karten, B. (2005) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2005.01.005 · Cited by 222 · see citing works
Overexpression of Human Apolipoprotein A-I Preserves Cognitive Function and Attenuates Neuroinflammation and Cerebral Amyloid Angiopathy in a Mouse Model of Alzheimer Disease
Lewis, T. L., Cao, D., Lu, H., Mans, R. A., Su, Y. R., Jungbauer, L. M., Linton, M. F., Fazio, S., LaDu, M. J., & Li, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127829 · Cited by 210 · see citing works
HDL and cognition in neurodegenerative disorders
Hottman, D. A., Chernick, D., Cheng, S., Wang, Z., & Li, L. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.015 · Cited by 184 · see citing works
Formation and function of apolipoprotein E-containing lipoproteins in the nervous system.
Vance, J., & Hayashi, H. (2010) · Biochimica et Biophysica Acta · doi:10.1016/j.bbalip.2010.02.007 · Cited by 185 · see citing works
Apolipoprotein A-I Deficiency Increases Cerebral Amyloid Angiopathy and Cognitive Deficits in APP/PS1ΔE9 Mice
Lefterov, I. M., Fitz, N. F., Cronican, A. A., Fogg, A., Lefterov, P., Kodali, R. B., Wetzel, R. B., & Koldamova, R. P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127738 · Cited by 129 · see citing works
Role of Cholesterol in APP Metabolism and Its Significance in Alzheimer’s Disease Pathogenesis
Maulik, M., Westaway, D. A., Jhamandas, J. H., & Kar, S. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8337-y · Cited by 117 · see citing works
Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease
Roher, A. E., Maarouf, C. L., Sue, L. I., Hu, Y., Wilson, J. R., & Beach, T. G. (2009) · Biomarkers · doi:10.3109/13547500903108423 · Cited by 108 · see citing works
HDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114 · see citing works
Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid
Perluigi, M., di Domenico, F., Fiorini, A., Cocciolo, A., Giorgi, A., Foppoli, C., Butterfield, D. A., Giorlandino, M., Giorlandino, C., Eugenia Schininà, M., et al. (2011) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201000121 · Cited by 97 · see citing works
Overexpression of Hsp27 ameliorates symptoms of Alzheimer's disease in APP/PS1 mice
Tóth, M. E., Szegedi, V., Varga, E., Juhász, G., Horváth, J., Borbély, E., Csibrány, B., Alföldi, R., Lénárt, N., Penke, B., et al. (2013) · Cell Stress and Chaperones · doi:10.1007/s12192-013-0428-9 · Cited by 89 · see citing works
The Endothelium Is Both a Target and a Barrier of HDL’s Protective Functions
Robert, J., Osto, E., & von Eckardstein, A. (2021) · Cells · doi:10.3390/cells10051041 · Cited by 88 · see citing works
Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer’s Disease in Non-Demented Elderly
Slot, R. E. R., van Harten, A. C., Kester, M. I., Jongbloed, W., Bouwman, F. H., Teunissen, C. E., Scheltens, P., Veerhuis, R., & van der Flier, W. M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151068 · Cited by 82 · see citing works
Lipid Metabolism and Glial Lipoproteins in the Central Nervous System
Hayashi, H. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.453 · Cited by 80 · see citing works
Cholesterol-related genes in Alzheimer's disease.
Wollmer, M. (2010) · Biochimica et Biophysica Acta · doi:10.1016/j.bbalip.2010.05.009 · Cited by 81 · see citing works
Dyslipidemia and Dementia: Current Epidemiology, Genetic Evidence, and Mechanisms Behind the Associations
Reitz, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110599 · Cited by 75 · see citing works
Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model
Katsouri, L., & Georgopoulos, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021880 · Cited by 72 · see citing works
ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice
Button, E. B., Boyce, G. K., Wilkinson, A., Stukas, S. K., Hayat, A., Fan, J., Wadsworth, B. J., Robert, J., Martens, K. M., & Wellington, C. L. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0497-9 · Cited by 71 · see citing works
Geranylgeranyl pyrophosphate stimulates γ‐secretase to increase the generation of Aβ and APP‐CTFγ
Zhou, Y., Suram, A., Venugopal, C., Prakasam, A., Lin, S., Yuan, S., Li, B., Paul, S. M., & Sambamurti, K. (2007) · The FASEB Journal · doi:10.1096/fj.07-8175com · Cited by 58 · see citing works
Self-citation
Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells
Panzenboeck, U., Kratzer, I., Sovic, A., Wintersperger, A., Bernhart, E. M., Hammer, A., Malle, E., & Sattler, W. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.01.013 · Cited by 55 · see citing works
Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer's disease
Fitz, N. F., Nam, K. N., Koldamova, R. P., & Lefterov, I. M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14668 · Cited by 50 · see citing works
Genetic Ablation of Apolipoprotein A-IV Accelerates Alzheimer's Disease Pathogenesis in a Mouse Model
Cui, Y., Huang, M., He, Y., Zhang, S., & Luo, Y. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.057 · Cited by 49 · see citing works
Naringenin: its chemistry and roles in neuroprotection
Atoki, A. V., Aja, P. M., Shinkafi, T. S., Ondari, E. N., & Awuchi, C. G. (2023) · Nutritional Neuroscience · doi:10.1080/1028415x.2023.2243089 · Cited by 46 · see citing works
Intravenous treatment with human recombinant ApoA-I Milano reduces beta amyloid cerebral deposition in the APP23-transgenic mouse model of Alzheimer's disease
de Retana, S. F., Montañola, A., Marazuela, P., Cuesta, M. D. L., Batlle, A., Fatar, M., Grudzenski, S., Montaner, J., & Hernández‐Guillamón, M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.08.028 · Cited by 44 · see citing works
The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimer’s Disease
Chernick, D., Zhong, R., & Li, L. (2020) · Biomolecules · doi:10.3390/biom10091276 · Cited by 38 · see citing works
Opposing effects ofApoe/Apoa1double deletion on amyloid-β pathology and cognitive performance in APP mice
Fitz, N. F., Tapias, V., Cronican, A. A., Castranio, E. L., Saleem, M., Carter, A. Y., Lefterova, M. I., Lefterov, I. M., & Koldamova, R. P. (2015) · Brain · doi:10.1093/brain/awv293 · Cited by 37 · see citing works
Sterols in the central nervous system
Mulder, M. T. (2009) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32832182da · Cited by 37 · see citing works
Apolipoprotein A1, the neglected relative of Apolipoprotein E and its potential role in Alzheimer’s disease
Endres, K. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.310669 · Cited by 36 · see citing works
Doxorubicin-Induced Thymus Senescence
Rukhsana Sultana, A., Domenico, F. D., Tseng, M. T., Cai, J., Noel, T. J., Chelvarajan, R. L., Pierce, W. M. J., Cini, C., Bondada, S., Clair, D. K. S., et al. (2010) · Journal of Proteome Research · doi:10.1021/pr100465m · Cited by 29 · see citing works
Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E
Robert, J., Button, E. B., Martin, E. M., McAlary, L., Gidden, Z., Gilmour, M., Boyce, G. K., Caffrey, T. M., Agbay, A. M., Clark, A., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00366-8 · Cited by 30 · see citing works
APP overexpression in the absence of NPC1 exacerbates metabolism of amyloidogenic proteins of Alzheimer's disease
Maulik, M., Peake, K., Chung, J.-Y., Wang, Y., Vance, J. E., & Kar, S. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv413 · Cited by 28 · see citing works
ApoA1, ApoJ and ApoE Plasma Levels and Genotype Frequencies in Cerebral Amyloid Angiopathy
Montañola, A., de Retana, S. F., López‐Rueda, A., Merino-Zamorano, C., Peñalba, A., Fernández‐Álvarez, P., Rodríguez‐Luna, D., Malagelada, A., Pujadas, F., Montaner, J., et al. (2015) · NeuroMolecular Medicine · doi:10.1007/s12017-015-8381-7 · Cited by 27 · see citing works
High-density lipoprotein-related cholesterol metabolism in Alzheimer's disease
Pedrini, S., Chatterjee, P., Hone, E., & Martins, R. N. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15170 · Cited by 22 · see citing works
High-Density Lipoprotein Mimetic Peptide 4F Efficiently Crosses the Blood-Brain Barrier and Modulates Amyloid-β Distribution between Brain and Plasma
Swaminathan, S. K., Zhou, A. L., Ahlschwede, K. M., Curran, G. L., Lowe, V. J., Li, L., & Kandimalla, K. K. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.265876 · Cited by 22 · see citing works
An ABCA1-independent pathway for recycling a poorly lipidated 8.1 nm apolipoprotein E particle from glia
Fan, J., Stukas, S. K., Wong, C. A., Chan, J., May, S., DeValle, N., Hirsch‐Reinshagen, V., Wilkinson, A., Oda, M. N., & Wellington, C. L. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m014365 · Cited by 23 · see citing works
Elevated plasma cholesterol does not affect brain Aβ in mice lacking the low‐density lipoprotein receptor
Elder, G. A., Cho, J. Y., English, D. F., Franciosi, S., Schmeidler, J., Sosa, M. A. G., Gasperi, R. D., Fisher, E. A., Mathews, P. M., Haroutunian, V., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04614.x · Cited by 26 · see citing works
Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease
Wirths, O., Thelen, K., Breyhan, H., Luzón-Toro, B., Hoffmann, K.-H., Falkai, P., Lütjohann, D., & Bayer, T. A. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.10.007 · Cited by 20 · see citing works
Endosomal-Lysosomal Cholesterol Sequestration by U18666A Differentially Regulates Amyloid Precursor Protein (APP) Metabolism in Normal and APP-Overexpressing Cells
Chung, J., Phukan, G., Vergote, D., Mohamed, A., Maulik, M., Stahn, M., Andrew, R. J., Thinakaran, G., Chaves, E., & Kar, S. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00529-17 · Cited by 18 · see citing works
Effects of cholesterol transport inhibitor U18666A on APP metabolism in rat primary astrocytes
Yang, H., Wang, Y., & Kar, S. (2017) · Glia · doi:10.1002/glia.23191 · Cited by 17 · see citing works
Statement of Principles for Health Care Journalists
Schwitzer, G. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020084 · Cited by 17 · see citing works
Knockout of apolipoprotein A‐I decreases parenchymal and vascular β‐amyloid pathology in the Tg2576 mouse model of Alzheimer's disease
Contu, L., Carare, R. O., & Hawkes, C. A. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12556 · Cited by 13 · see citing works
Organelle perturbation in Alzheimer’s disease: do intracellular amyloid-ß and the fragmented Golgi mediate early intracellular neurotoxicity?
Fourrière, L., & Gleeson, P. A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1550211 · Cited by 6 · see citing works
Plasma Amyloid-β in Patients with Tangier Disease
Shahim, P., Bochem, A. E., Mattsson, N., Lautner, R., Blennow, K., Hovingh, G. K., Motazacker, M. M., & Zetterberg, H. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122425 · Cited by 3 · see citing works
Analysis of Serum Cholesterol Efflux Capacity in a Minipig Model of Nonischemic Heart Failure
Bigazzi, F., Adorni, M. P., Puntoni, M., Sbrana, F., Lionetti, V., Pino, B. D., Favari, E., Recchia, F. A., Bernini, F., & Sampietro, T. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.37101 · Cited by 3 · see citing works
Cholesterol Trafficking in the Brain
Lütjohann, D., Vanmierlo, T., & Mulder, M. (2009) · Springer eBooks · doi:10.1007/978-3-642-00300-4_5 · Cited by 4 · see citing works
Cholesterol Disturbances in Inherited Neurodegenerative Diseases : Studies on Npc1, Ppt1 and Ctsd deficient mice
Mutka, A. (2009) · Työväentutkimus Vuosikirja
Non‐amyloid Approaches To Alzheimer's Disease
Veng, L., Savage, M. J., Barrow, J. C., & Zerbinatti, C. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc253
ABCA1, Apoe and apoA-I As Potential Therapeutic Targets for Treating Alzheimer’s Disease
Namjoshi, D., Stukas, S. K., & Wellington, C. L. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.23
Cholesterol Disturbances in Inherited Neurodegenerative Diseases
Mutka, A. (2009)
Authors' Reply
Gandy, S., & Petanceska, S. S. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020085
Additional file 1 of Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E
Robert, J., Button, E. B., Martin, E. M., McAlary, L., Gidden, Z., Gilmour, M., Boyce, G. K., Caffrey, T. M., Agbay, A. M., Clark, A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12033156

Independent effects of APOE on cholesterol metabolism and brain A levels in an Alzheimer disease mouse model
Mann, K. M. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh199 · Cited by 48 · see citing works
Elevated plasma cholesterol does not affect brain Aβ in mice lacking the low‐density lipoprotein receptor
Elder, G. A., Cho, J. Y., English, D. F., Franciosi, S., Schmeidler, J., Sosa, M. A. G., Gasperi, R. D., Fisher, E. A., Mathews, P. M., Haroutunian, V., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04614.x · Cited by 26 · see citing works
P‐161: Amyloid beta (Aβ) is unaltered with highly elevated peripheral cholesterol in mice lacking the low‐density lipoprotein receptor
Franciosi, S., English, D. F., Cho, J. Y., Buxbaum, A. R., Schmidt, S. D., Perez, G. M., Mathews, P. M., Gasperi, R. D., Sosa, M. A. G., Haroutunian, V. H., et al. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.04.124
Changes in Apolipoprotein E Expression in Response to Dietary and Pharmacological Modulation of Cholesterol
Petanceska, S. S., DeRosa, S., Sharma, A., Diaz, N. S., Duff, K., Tint, S. G., Refolo, L. M., & Pappolla, M. A. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:395 · Cited by 50 · see citing works
Absence of ApoE Upregulates Murine Brain ApoD and ABCA1 Levels, But Does Not Affect Brain Sterol Levels, While Human ApoE3 and Human ApoE4 Upregulate Brain Cholesterol Precursor Levels
Jansen, P. J., Lütjohann, D., Thelen, K., von Bergmann, K., Leuven, F. V., Ramaekers, F., & Monique, M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1150 · Cited by 39 · see citing works

Authors: Fagan, A. M., Christopher, E., Taylor, J. W., Parsadanian, M., Spinner, M., Watson, M., Fryer, J. D., Wahrle, S., Bales, K. R., Paul, S. M., & Holtzman, D. M.
Affiliations: Washington University in St. Louis (US)
Eli Lilly (United States) (US)
Corresponding author: Fagan, Anne M.
ORCID: Fagan, Anne M.
Taylor, Jennie W.
Spinner, Michael
Fryer, John D.
Paul, Steven M.
Holtzman, David M.
Venue: The American Journal of Pathology
Publisher: Elsevier BV
Published: 2004-10
Volume: 165
Issue: 4
Pages: 1413-1422
ISSN: 0002-9440 (ISSN-L)
DOI: 10.1016/s0002-9440(10)63399-8
PMC: PMC1618648
OpenAlex: W2028125541
Cited by: 54
References: 80
Citations by year: 2025: 1 · 2023: 1 · 2021: 2 · 2020: 5 · 2019: 4 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 2 · 2012: 3
FWCI: 1.85
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: American Journal Of Pathology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (AG05681, 1K01-AG00861–01, AG13956, AG11355)
Alzheimer's Association
Topics: Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: serum cholesterol, amyloid-beta pathology, Alzheimer's disease, cerebral amyloidosis, high-density lipoprotein, brain cholesterol, apolipoprotein E, cholesterol metabolism, amyloid-beta metabolism
MeSH terms: Alzheimer Disease, Amyloidosis, Animals, Brain Diseases, Cholesterol, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Genotype, Mice, Transgenic, Blotting, Western, Amyloid beta-Peptides, Apolipoprotein A-I, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-β pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks